Literature DB >> 23902707

Monoamine transporters: structure, regulation, and clinical implications.

Eduardo E Benarroch1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23902707     DOI： 10.1212/WNL.0b013e3182a1ab4a

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  10 in total

1.  A patient with PMP22-related hereditary neuropathy and DBH-gene-related dysautonomia.

Authors:  Anna Bartoletti-Stella; Giacomo Chiaro; Giovanna Calandra-Buonaura; Manuela Contin; Cesa Scaglione; Giorgio Barletta; Annagrazia Cecere; Paolo Garagnani; Paolo Tieri; Alberto Ferrarini; Silvia Piras; Claudio Franceschi; Massimo Delledonne; Pietro Cortelli; Sabina Capellari
Journal:  J Neurol       Date:  2015-09-26       Impact factor: 4.849

Review 2.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

3.  SERT and uncertainty: serotonin transporter expression influences information processing biases for ambiguous aversive cues in mice.

Authors:  S B McHugh; C Barkus; J Lima; L R Glover; T Sharp; D M Bannerman
Journal:  Genes Brain Behav       Date:  2015-04-17       Impact factor: 3.449

4.  Dopamine transporter single-photon emission computerized tomography supports diagnosis of akinetic crisis of parkinsonism and of neuroleptic malignant syndrome.

Authors:  G Martino; M Capasso; M Nasuti; L Bonanni; M Onofrj; A Thomas
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

5.  Zebrafish Get Connected: Investigating Neurotransmission Targets and Alterations in Chemical Toxicity.

Authors:  Katharine A Horzmann; Jennifer L Freeman
Journal:  Toxics       Date:  2016-08-27

6.  Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients.

Authors:  Elisa Schmidt; Christian Schinke; Michael Rullmann; Julia Luthardt; Georg-Alexander Becker; Sarah Haars; Muriel Stoppe; Donald Lobsien; Karl-Titus Hoffmann; Osama Sabri; Swen Hesse; Florian Then Bergh
Journal:  Sci Rep       Date:  2020-09-04       Impact factor: 4.379

7.  Neuroinflammation and amyloid-beta 40 are associated with reduced serotonin transporter (SERT) activity in a transgenic model of familial Alzheimer's disease.

Authors:  Athanasios Metaxas; Marco Anzalone; Ramanan Vaitheeswaran; Sussanne Petersen; Anne M Landau; Bente Finsen
Journal:  Alzheimers Res Ther       Date:  2019-05-01       Impact factor: 6.982

Review 8.  Chemical and Genetic Zebrafish Models to Define Mechanisms of and Treatments for Dopaminergic Neurodegeneration.

Authors:  Ola Wasel; Jennifer L Freeman
Journal:  Int J Mol Sci       Date:  2020-08-20       Impact factor: 5.923

9.  Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice.

Authors:  Iara Pérez-Taboada; Samuel Alberquilla; Eduardo D Martín; Rishi Anand; Stefania Vietti-Michelina; Nchimunya N Tebeka; James Cantley; Stephanie J Cragg; Rosario Moratalla; Mario Vallejo
Journal:  Mov Disord       Date:  2020-07-15       Impact factor: 10.338

Review 10.  Glycine Transporter 2: Mechanism and Allosteric Modulation.

Authors:  Zachary J Frangos; Ryan P Cantwell Chater; Robert J Vandenberg
Journal:  Front Mol Biosci       Date:  2021-11-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.